Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Cytokinetics (CYTK)

Cytokinetics (CYTK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,064,108
  • Shares Outstanding, K 104,576
  • Annual Sales, $ 7,530 K
  • Annual Income, $ -526,240 K
  • 60-Month Beta 0.68
  • Price/Sales 930.49
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade CYTK with:

Options Overview Details

View History
  • Implied Volatility 96.10% ( +0.75%)
  • Historical Volatility 38.94%
  • IV Percentile 77%
  • IV Rank 20.21%
  • IV High 291.99% on 12/19/23
  • IV Low 46.50% on 09/15/23
  • Put/Call Vol Ratio 0.79
  • Today's Volume 2,775
  • Volume Avg (30-Day) 3,058
  • Put/Call OI Ratio 0.82
  • Today's Open Interest 185,823
  • Open Int (30-Day) 176,296

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -1.16
  • Number of Estimates 11
  • High Estimate -0.92
  • Low Estimate -1.35
  • Prior Year -1.38
  • Growth Rate Est. (year over year) +15.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
64.82 +4.22%
on 04/19/24
75.71 -10.78%
on 04/09/24
-0.04 (-0.06%)
since 03/19/24
3-Month
61.33 +10.14%
on 03/14/24
84.92 -20.45%
on 01/23/24
-13.41 (-16.56%)
since 01/19/24
52-Week
25.98 +160.01%
on 10/04/23
110.25 -38.73%
on 01/08/24
+29.62 (+78.09%)
since 04/19/23

Most Recent Stories

More News
2 Incredible Growth Stocks to Buy Right Now

These two biotech stocks could be big winners in the years ahead.

CYTK : 67.55 (+0.82%)
VKTX : 63.42 (-1.93%)
Cytokinetics: Q4 Earnings Snapshot

Cytokinetics: Q4 Earnings Snapshot

CYTK : 67.55 (+0.82%)
Markets Today: Stocks Slip on Hawkish Fed Comments

Morning Markets March E-Mini S&P 500 futures (ESH24 ) are down -0.30%, and March Nasdaq 100 E-Mini futures (NQH24 ) are down -0.19%. Stock index futures this morning are mildly lower as higher bond yields...

ESM24 : 5,016.25 (+0.25%)
NQM24 : 17,241.50 (+0.35%)
BA : 169.82 (-0.24%)
APD : 231.64 (-0.59%)
ZS : 169.21 (-2.17%)
MAT : 18.05 (-0.66%)
CYTK : 67.55 (+0.82%)
GWW : 942.65 (+0.55%)
CAT : 354.66 (-0.55%)
EL : 144.41 (-0.28%)
FDMT : 25.25 (+1.90%)
CTLT : 55.48 (-0.57%)
2 Biotechs That Could Get Bought Out in 2024

These two biotechs have been frequent visitors to the buyout-rumor mill and for good reason.

CYTK : 67.55 (+0.82%)
BBIO : 24.74 (-0.84%)
Cytokinetics, New York Times rise; Iovance Biotherapeutics fall, Wednesday, 12/27/2023

Stocks that are trading heavily or have substantial price changes on Wednesday: Cytokinetics, New York Times rise; Iovance Biotherapeutics fall

CYTK : 67.55 (+0.82%)
NEM : 39.02 (+1.22%)
TMUS : 162.33 (+0.92%)
FCX : 49.61 (-1.10%)
TM : 228.72 (-1.35%)
CHRS : 2.07 (+3.50%)
NYT : 42.60 (+1.99%)
Cytokinetics: Q3 Earnings Snapshot

Cytokinetics: Q3 Earnings Snapshot

CYTK : 67.55 (+0.82%)
Cytokinetics: Q2 Earnings Snapshot

Cytokinetics: Q2 Earnings Snapshot

CYTK : 67.55 (+0.82%)
Cytokinetics (CYTK) Reports Q1 Loss, Tops Revenue Estimates

Cytokinetics (CYTK) delivered earnings and revenue surprises of -11.29% and 163.60%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

CYTK : 67.55 (+0.82%)
GERN : 3.69 (-1.07%)
Cytokinetics: Q1 Earnings Snapshot

Cytokinetics: Q1 Earnings Snapshot

CYTK : 67.55 (+0.82%)
Earnings Preview: Urogen Pharma (URGN) Q1 Earnings Expected to Decline

Urogen Pharma (URGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

URGN : 13.73 (-3.72%)
CYTK : 67.55 (+0.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology...

See More

Key Turning Points

3rd Resistance Point 71.61
2nd Resistance Point 69.71
1st Resistance Point 68.63
Last Price 67.55
1st Support Level 65.64
2nd Support Level 63.74
3rd Support Level 62.66

See More

52-Week High 110.25
Fibonacci 61.8% 78.06
Fibonacci 50% 68.11
Last Price 67.55
Fibonacci 38.2% 58.17
52-Week Low 25.98

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar